Background: Chronic complications of diabetes involve microvascular illness, macrovascular illness, and neuropathy. Many cases with type 2 diabetes need numerous glucose-lowering medications to achieve adequate control. Imeglimin is a new oral antidiabetic agent that enhances glucose-stimulated insulin secretion while preserving β-cell mass and improving insulin sensitivity. Aim of the study: This work has been designed to explore the influence of imeglimin alone and in combination with empagliflozin and linagliptin on diabetic infarcted mice and some of their related complications. Methods: Mice were randomized into 7groups (8 rats for each): control group, diabetic-untreated group, Imeglimin treated diabetic group (177 mg/kg/ day, orally), Linagliptin treated group (3 mg/Kg/day, orally), empagliflozin treated group (10 mg/kg/day, orally), Imeglimin and Linagliptin treated Group, Imeglimin and Empagliflozin treated group. Treated groups received drugs for 4 weeks following the induction of diabetes mellitus. this research examined the therapeutic effect of Imeglimin, Linagliptin, and Empagliflozin against diabetes mellitus induced by HFD&STZ in rats via hemato-biochemical, histological, and immunohistological evaluations. Results: The treated groups restored the hemato-biochemical, histological, and immunohistological pictures toward normality. Conclusion: Our study showed that Imeglimin exerts dual insulinotropic and insulin-sensitizing effects in treating T2DM, while linagliptin and empagliflozin significantly reduce FBG and HbA1c to improve glycemic control. However, imeglimin demonstrates superior efficacy. the combined therapy was superior to each medication alone in enhancing all parameters. |
